SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-044690
Filing Date
2024-02-23
Accepted
2024-02-23 17:17:06
Documents
17
Period of Report
2024-02-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d762897d8k.htm   iXBRL 8-K 32125
2 EX-5.1 d762897dex51.htm EX-5.1 9808
3 EX-99.1 d762897dex991.htm EX-99.1 10283
7 GRAPHIC g762897g0223130044656.jpg GRAPHIC 2668
  Complete submission text file 0001193125-24-044690.txt   186587

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ntla-20240223.xsd EX-101.SCH 2847
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20240223_lab.xml EX-101.LAB 17994
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20240223_pre.xml EX-101.PRE 11259
18 EXTRACTED XBRL INSTANCE DOCUMENT d762897d8k_htm.xml XML 3637
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 24672619
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)